<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Article Tag Suite 1.1//EN"
  "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         article-type="research-article"
         xml:lang="en">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>American Journal of Pharmacy and Health Research</journal-title>
        <abbrev-journal-title abbrev-type="publisher">AJPHR</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub">2321-3647</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.46624/ajphr.2020.v8.i9.004</article-id>
      <article-id pub-id-type="publisher-id">AJPHR809004</article-id>
      <title-group>
        <article-title>A Prospective Open Label Randomized Clinical Study of Compound Unani Formulation (Ustukhuddoos, Filfil Siyah, Aslussoos) in the Management of Iltihab-e-Tajaweef-e-Anaf Muzmin (Chronic Sinusitis).</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Arfi</surname>
            <given-names>Md Zahid</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rahman</surname>
            <given-names>Md Razi Ahmad2 Md
Najibur</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Alam</surname>
            <given-names>Md
Tanwir</given-names>
          </name>
        </contrib>
      </contrib-group>
      <pub-date pub-type="epub" iso-8601-date="2020-09-01">
        <month>09</month>
        <day>01</day>
        <year>2020</year>
      </pub-date>
      <volume>8</volume>
      <issue>9</issue>
      <abstract>
        <p>ABSTRACTTajaweef-e-Anaf (Sinusitis) has tremendous impact on public health. It is the 5th known case of population16,17. Under such circumstances, the Unani medicine has proven its own importance regarding its efficacy, cost and minimal side effects. The present study was designed as an open label randomized clinical trial in successive patients with chronic sinusitis diagnosed on presentation, history and investigations. Sixty diagnosed patients of age between 15-60 years. Who belongs to inclusion criteria were registered, and compound Unani formulation (Ustukhuddoos, Filfil Siyah, Aslussoos) is given for 45 days. Complete physical examination &amp; investigations of patients were done and follow-up planned prior of trial, 15th 30th day and at the end of trial. Subjective objective and safety parameter recorded. On objective parameters, there are two sub headings, pathological investigation and radiological examination. In Radiological examination, Calculating by Chi-square p-Value is 0.001 which is significant. While in pathological investigation in TLC, Lymphocyte, Eosinophils “P” value is 0.001, which is very significant. Haemoglobin “P” value is 0.517 and Monocyte, “P” value 0.088 which is not significant. Keywords: Tajaweef-e-Anaf; Ustukhuddoos; Filfil Siyah; Aslussoos; Unani Medicine.</p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>Tajaweef-e-Anaf</kwd>
        <kwd>Ustukhuddoos</kwd>
        <kwd>Filfil Siyah</kwd>
        <kwd>Aslussoos</kwd>
        <kwd>Unani Medicine.</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <!-- Full article body not available in metadata-only JATS export. See PDF/HTML galley. -->
  </body>
  <back/>
</article>
